Q3 EPS Estimates for Longeveron Raised by Zacks Small Cap

Key Takeaways:

• Zacks Small Cap raised its Q3 2025 EPS estimate for Longeveron.
• The new projection calls for a loss of $0.26 per share.
• Analyst B. Sorensen issued the revision in a research note dated Aug. 14.
• Longeveron is traded on Nasdaq under the ticker LGVN.
• The adjustment suggests a slightly improved short-term outlook for the company.

Analyst Revision
In a brief yet telling research note dated Aug. 14, Zacks Small Cap analyst B. Sorensen “boosted” expectations for Longeveron Inc.’s third-quarter 2025 results. The firm now sees the Miami-based biotech posting a loss of $0.26 per share—an improvement from its previous view, according to the note shared with clients.

The Number: Minus $0.26
“Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($0.26) for the quarter,” the report states. While the figure remains in negative territory, even a modest upward revision can matter for investors tracking a clinical-stage enterprise whose path to profitability is often measured in incremental steps.

Who Made the Call
Zacks Small Cap, a unit of the broader Zacks investment-research franchise, focuses on emerging companies outside the large-cap spotlight. Its fresh take on Longeveron arrives just weeks before the company is due to report its results, giving portfolio managers one more data point to weigh.

Market Context
Longeveron, which trades on the Nasdaq under the symbol LGVN, operates in the highly volatile biotech sector, where analyst sentiment can swing quickly. An upward adjustment—no matter how small—signals that at least one watcher sees slightly less red ink ahead.

Looking Ahead
Quarterly earnings estimates frequently shift as new information filters in, but each revision offers a snapshot of evolving expectations. For Longeveron, the latest snapshot shows a slimmer loss and a bit more breathing room as the company works toward its long-term goals.